Rights Offering Authorization
Company: Core Scientific
The claim, verbatim
Company authorized rights offering of up to $55 million of Common Stock for holders of Old Common Stock as of November 16, 2023.
Source (primary)
Core Scientific SC 13D/A filed 2024-02-20 (SEC EDGAR, sec_filing)
View cached copy (2026-08-31)Live source ↗
Quote: “holders of the Issuer's Old Common Stock as of November 16, 2023 were granted the right to participate in a rights offering (the " Rights Offering ") for the purchase, on a pro rata basis, of up to $55 million of Common Stock to be issued pursuant to the Plan.”
How we checked this
Checked on September 18, 2026. The cited source supports every part of this claim.
The filing states that, in accordance with the court-approved Plan, holders of Old Common Stock as of November 16, 2023 could participate pro rata in a rights offering of up to $55 million of Common Stock.
Confirmed in the source:
- Under Core Scientific's reorganization plan, a rights offering was made for up to $55 million of common stock
- Holders of Old Common Stock as of November 16, 2023 were eligible to participate in the rights offering
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1839341/000119312524040115/d784237dsc13da.htm) in full (14,080 characters, retrieved August 31, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific SC 13D/A filed 2024-02-20
Quote: “holders of the Issuer's Old Common Stock as of November 16, 2023 were granted the right to participate in a rights offering (the " Rights Offering ") for the purchase, on a pro rata basis, of up to $55 million of Common Stock to be issued pursuant to the Plan.”